GGrantIndex
← Leaderboards

Harold I Saavedra

Ohio State University

$5,351,064
Attributed
$6,894,502
Total exposure
8
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,696,199 · 9

By mechanism

U54$5,530,985 · 6
R01$4,427,320 · 2
K01$737,894 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsCancer CenterCentrosomePathway InteractionsGrowthHealth SciencesResearch PersonnelCell LineMalignant Breast NeoplasmUniversitiesTumorCellsPhosphorylationPuerto RicoTissue MicroarrayGenetic TranscriptionAneuploidyChromosomal InstabilityProgramsAffectOverexpressionMammary NeoplasmsHispanicInstitution

Grant awards (28)

(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership #$1,301,440
U54 · FY2025 · CA · contact PI
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.$1,079,390
R01 · FY2025 · CA · contact PI
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.$239,942
R01 · FY2025 · CA · contact PI
Administrative Core$144,606
U54 · FY2025 · CA · contact PI
PILOT PROJECT 2: Understanding the biology of an ADCK4-NUMBL fusion in lung adenocarcinoma aggressiveness$144,604
U54 · FY2025 · CA · contact PI
Planning and Evaluation Core$144,604
U54 · FY2025 · CA · contact PI
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership #$1,198,817
U54 · FY2024 · CA · contact PI
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.$486,917
R01 · FY2024 · CA · contact PI
Targeting centrosome-mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas. Supplement1$117,166
R01 · FY2024 · CA · contact PI
Planning and Evaluation Core$79,729
U54 · FY2024 · CA · contact PI
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership #$1,301,440
U54 · FY2023 · CA · contact PI
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.$487,437
R01 · FY2023 · CA · contact PI
Planning and Evaluation Core$144,604
U54 · FY2023 · CA · contact PI
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.$483,219
R01 · FY2022 · CA · contact PI
Planning and Evaluation Core$540,515
U54 · FY2021 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$173,579
U54 · FY2019 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$178,948
U54 · FY2018 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$178,099
U54 · FY2017 · CA · contact PI
Nek2 and NPM in centrosome amplification$301,007
R01 · FY2014 · CA · contact PI
Nek2 and NPM in centrosome amplification$291,697
R01 · FY2013 · CA · contact PI
Nek2 and NPM in centrosome amplification$310,316
R01 · FY2012 · CA · contact PI
Nek2 and NPM in centrosome amplification$310,316
R01 · FY2011 · CA · contact PI
Nek2 and NPM in centrosome amplification$319,913
R01 · FY2010 · CA · contact PI
E2F3: a suppressor of centrosome amplification$157,113
K01 · FY2008 · CA · contact PI
E2F3: a suppressor of centrosome amplification$157,113
K01 · FY2007 · CA · contact PI
E2F3: a suppressor of centrosome amplification$157,113
K01 · FY2006 · CA · contact PI
E2F3: a suppressor of centrosome amplification$157,113
K01 · FY2005 · CA
E2F3: a suppressor of centrosome amplification$109,442
K01 · FY2004 · CA